This PGD is for the administration of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (dTaP/IPV) to individuals from 3 years 4 months to under 10 years of age, in accordance with the national immunisation programme in England, or for the management of cases and contacts of diphtheria, tetanus, pertussis or poliomyelitis from 3 years of age.

This PGD is for the administration of diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis, Haemophilus influenzae type b and hepatitis B (DTaP/IPV/Hib/HepB) vaccine to individuals from 6 weeks (routinely at 8 weeks) to under 10 years of age in accordance with the national immunisation programme or for the management of cases and contacts identified in an outbreak of polio in accordance with the National polio guidelines: Local and regional services and recommendations from the local health protection team.

This PGD is for the administration of Haemophilus influenzae type b and meningococcal C conjugate vaccine (Hib/MenC) to individuals from their first birthday to under 10 years of age in accordance with the national immunisation programme; and to individuals of any age for the prevention of secondary cases of meningococcal group C (MenC) disease.

This PGD is extended and valid until 31 July 2025 ahead of the discontinuation of Hib/MenC (Menitorix®) and pending introduction of changes to the childhood vaccination programme.

This PGD is for the administration of Hepatitis B recombinant DNA (rDNA) vaccine (adsorbed) to individuals considered at increased risk of exposure to hepatitis B virus, at increased risk of complications of hepatitis B disease, or post potential exposure to hepatitis B virus.

This PGD is extended and valid until 31 October 2025, pending anticipated revisions to the childhood immunisation programme and the impact of changes to the infant
hexavalent regime on advice provided in the hepatitis B PGD.

This PGD is for the administration of Hepatitis B recombinant DNA (rDNA) vaccine
(adsorbed) to individuals who are 15 years of age or over and are on haemodialysis, a renal transplantation programme or have chronic renal failure that is likely to require
haemodialysis or transplant.

This PGD is for the administration of human papillomavirus (HPV) vaccine to individuals from 12 years of age or from school year 8 and aged less than 25 years in accordance with the national immunisation programme.

This PGD is for the administration of meningococcal groups A, C, W and Y conjugate vaccine (MenACWY) to individuals eligible for the national routine MenACWY vaccination programme or
identified as a contact of a case of invasive meningococcal disease, in accordance with the Green Book and Guidance for Public Health Management of Meningococcal Disease in the UK.

This PGD is for the administration of meningococcal group A, C, W, and Y conjugate vaccine
(MenACWY) to individuals with an underlying medical condition which puts them at increased
risk from Neisseria meningitidis.

This PGD is extended and valid until 31 August 2025, pending anticipated revisions to the childhood immunisation programme and the withdrawal of Hib/MenC (Menitorix®)
vaccine.

This PGD is for the administration of meningococcal group B vaccine (rDNA, component, adsorbed) (4CMenB) to individuals from 8 weeks of age eligible for the national routine
immunisation programme and to individuals for the prevention of secondary cases of meningococcal group B disease.

This PGD is for the administration of meningococcal group B vaccine (rDNA, component, adsorbed) (4CMenB) to individuals, from 2 years of age, with an underlying medical condition which puts them at increased risk from Neisseria meningitidis group B.

This PGD is for the administration of measles, mumps and rubella (MMR) vaccine to individuals from one year of age for routine immunisation, or from 6 months of age if early protection is required, in accordance with the national immunisation programme and the National measles guidelines.

This PGD is for the administration of the non-replicating, live modified vaccinia virus Ankara -Bavarian Nordic (MVA-BN), to individuals identified for immunisation in response to preventing the spread of monkeypox virus (MPXV). This PGD allows the use of Imvanex® vaccine and where Jynneos® is supplied, this PGD only enables the use of US licensed Batch FDP00072, expiry 31 July 2025.

This PGD is for the administration of low dose diphtheria, tetanus and acellular pertussis-containing vaccine, with or without inactivated poliomyelitis (Tdap or dTaP/IPV) to pregnant women from week 16 of pregnancy, in accordance with the national immunisation programme and to pertussis contacts aged 10 years and over in accordance with Guidelines for the Public Health Management of Pertussis in England and Guidelines for the Public Health Management of Pertussis Incidents in Healthcare Settings.

This PGD is for the administration of pneumococcal polysaccharide conjugate vaccine (13-valent or 15-valent, adsorbed) (PCV) to individuals from 12 weeks to under 2 years of age in accordance with the national immunisation programme for active immunisation against pneumococcal disease and to individuals from 6 weeks of age recommended PCV13 or PCV15 in response to an outbreak of pneumococcal disease.

This PGD is for the administration of pneumococcal polysaccharide conjugate vaccine (13-valent or 15-valent, adsorbed) (PCV) to individuals from 6 weeks of age with an underlying medical condition which puts them at increased risk from pneumococcal disease.

This PGD is for the administration of 23-valent pneumococcal polysaccharide vaccine (PPV23) to individuals from 65 years of age and individuals from 2 years of age in a clinical risk group in accordance with the national immunisation programme for active immunisation against pneumococcal disease and UK guidelines for the public health management of clusters of severe pneumococcal disease in closed settings.

This PGD is for the administration of Respiratory Syncytial Virus (RSV) vaccine to individuals eligible for the national vaccination programme aged 75 years and over and for individuals who are pregnant, from week 28 of pregnancy.

This PGD is for the administration of rotavirus vaccine (live) to infants aged 6 weeks to 23 weeks and 6 days for active immunisation against rotavirus.

This PGD is for the administration of Shingrix® Herpes Zoster Vaccine (recombinant, adjuvanted),
for the prevention of herpes zoster (‘zoster’ or shingles) and herpes zoster-related post-herpetic
neuralgia (PHN), to individuals who are eligible for the national shingles immunisation programme.

This PGD is for the administration of low-dose diphtheria, tetanus and inactivated poliomyelitis vaccine (Td/IPV) to individuals from 10 years of age. This PGD supports delivery of the school-age booster from Year 9 onwards in accordance with the national immunisation programme in England. This PGD is also used for the administration of Td/IPV vaccine for the management of tetanus-prone wounds and cases and contacts of either diphtheria or poliomyelitis in an outbreak according to respective national guidelines. The PGD may also be used for individuals travelling to high-risk areas.

This PGD is for the administration of varicella vaccine (live) to individuals identified for pre exposure prophylaxis, and where chickenpox is co-circulating with Group A Streptococcus (GAS) infections, for post exposure prophylaxis in non immune children, from 9 months of age and adults in accordance with national guidelines.

This PGD is for the administration of typhoid Vi polysaccharide vaccine to overseas travellers at risk of exposure to Salmonella enterica serovar typhi (S. typhi) in accordance with recommendations from the National Travel Health Network and Centre (NaTHNaC).

This PGD is for the administration of hepatitis A virus (inactivated) and hepatitis B recombinant DNA (rDNA) (HepA/B) vaccine (adsorbed) to individuals requiring protection against hepatitis A and hepatitis B virus in accordance with national recommendations.

This PGD is for the administration of Hepatitis A virus (inactivated) vaccine (adsorbed), to individuals considered at high risk of exposure to hepatitis A or post exposure to hepatitis A
virus in accordance with national recommendations.